RNA therapeutics for kidney injury

Goleij, Pouya; Sanaye, Pantea Majma; Rezaee, Aryan; Tabari, Mohammad Amin Khazeei; Arefnezhad, Reza; Motedayyen, Hossein

doi:10.1016/bs.pmbts.2023.12.007

Cited by 1 publication

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, biallelic deletion of Dicer1, a crucial enzyme for miRNA biogenesis, has been associated with the development of highly aggressive angiosarcomas [60]. This observation highlights the potential of utilizing antagonistic miRNAs or miRNA mimetics for angiosarcoma therapy [8]. Garcia-Heredia et al examined miRNA expression in 17 sarcomas and 6 nontumor mesenchymal tissues and compared them to the IMR90 cell line to find differentially expressed miRNAs.…”

Section: Micrornas and Angiosarcomamentioning

confidence: 99%

“…This regulatory influence extends to an estimated 60% of human genes, highlighting their widespread impact (5). Consequently, miRNAs are attracting significant interest as potential targets for the prevention, diagnosis, and treatment of complex human diseases (6)(7)(8). Emerging evidence underscores the critical role of miRNAs in maintaining cellular homeostasis by tightly regulating diverse biological functions (9,10).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs and angiosarcoma: are there promising reports?

Modarresi Chahardehi,

Afrooghe,

Emtiazi

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations in the expression of specific miRNA subtypes. A substantial body of evidence underscores the pivotal involvement of miRNAs in the genesis of angiosarcoma and certain cardiovascular tumors. This review aims to delve into the current literature on miRNAs and their prospective applications in cardiovascular malignancies, with a specific focus on angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, and potential treatments while providing a recapitulation of angiosarcoma’s risk factors and molecular pathogenesis, with an emphasis on the role of miRNAs. These insights can serve as the groundwork for designing randomized control trials, ultimately facilitating the translation of these findings into clinical applications. Moving forward, it is imperative for studies to thoroughly scrutinize the advantages and disadvantages of miRNAs compared to current diagnostic and prognostic approaches in angiosarcoma and other cardiovascular tumors. Closing these knowledge gaps will be crucial for harnessing the full potential of miRNAs in the realm of angiosarcoma and cardiovascular tumor research.

show abstract

Section: Micrornas and Angiosarcomamentioning

confidence: 99%